James Hurst, Kirkland & Ellis (Photo: Todd Winters)
The notorious 100-plus patent thicket that AbbVie Inc. planted around biologic drug Humira—and the company’s deals with competitors to enter the market—do not run afoul of federal antitrust laws.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]